Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.
Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on February 5, 2025, was executed at a price of $88.50 per share, amounting to a ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...
Hosted on MSN3d
What Are Wall Street Analysts’ Target Price for Merck Stock?Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...
Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.
New Jersey, which is in the New York City metropolitan area. The current incarnation of Merck went public in January of 1978. Now it competes with or is similar to, among others: The company ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback